Biotech

All Articles

iTeos- GSK's TIGIT celebrity reveals meaningful remodeling

.After declaring a phase 3 launch based upon favorable midstage outcomes, iTeos and also GSK are las...

More collaborative FDA may accelerate uncommon disease R&ampD: file

.The FDA should be actually extra available and joint to discharge a surge in commendations of rare ...

Zenas, MBX, Bicara scalp to Nasdaq in hot time for biotech IPOs

.It's an extraordinarily occupied Friday for biotech IPOs, along with Zenas BioPharma, MBX as well a...

Atea's COVID antiviral falls short to halt hospitalizations in phase 3

.Atea Pharmaceuticals' antiviral has actually failed yet another COVID-19 test, yet the biotech stil...

Neurocrine's quote to conserve schizophrenia possibility stops working

.Neurocrine Biosciences' schizophrenia program pivot has actually failed. The biotech was not able t...

Sanofi spends $110M upfront for late-stage radioligand therapy

.Sanofi has actually made a late entry to the radioligand party, spending 100 thousand euros ($ 110 ...

F 2G brings up $100M for 2nd attempt to get brand-new antifungal to market

.After F2G's first try to obtain a new lesson of antifungal to market was actually thwarted by the F...

Moderna targets $1.1 B in R&ampD spending cuts, falls 5 courses surrounded by success tensions

.Moderna has promised to cut R&ampD costs by $1.1 billion through 2027. The choice to shrink the spe...

Sanofi's $80M bet on Key dystrophy drug ends in stage 3 lose big

.Just four months after Sanofi wager $80 million in upfront cash money on Fulcrum Rehabs' losmapimod...

Oncternal equity drains 60% among discharges, test discontinuations

.Cancer provider Oncternal Rehabs is actually folding all its scientific tests and also giving up te...